A federal appeals court upholds Abiomed's win in a shareholders lawsuit accusing the company of inflating its stock price with rosy predictions for its flagship Impella 2.5 heart pump.
Abiomed (NSDQ:ABMD) logged another win in a shareholders lawsuit accusing it and its management of misleading investors over the prospects for its flagship Impella 2.5 heart pump.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1Aas3jA
Cap comentari:
Publica un comentari a l'entrada